Cenduit Participates in QuintilesIMS Webinar to Share Tips on Continuous Glucose Monitoring (CGM) in Clinical Trials

RESEARCH TRIANGLE PARK, NC, UNITED STATES - Oct 24, 2016 - Cenduit, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is participating in a free webinar hosted by QuintilesIMS, where expert guest speakers will highlight regulatory trends, technology innovation and industry perspectives surrounding Continuous Glucose Monitoring (CGM) to help sponsors develop smarter diabetes clinical trials.   

In this webinar, experts Sam Osman, CEO of Cenduit; Rich Yang, vice president of Corporate Sales and Connected Solutions at Dexom; Dr. Paul Strumph, vice president of Clinical Development at Lexicon Pharmaceuticals; and Dr. Richard Bergenstal, executive director of International Diabetes Center (IDC) at Park Nicollet, will walk through the competitive diabetes clinical development landscape and how CGM has the potential to become the new gold-standard in clinical trials. The webinar will provide tips for navigating the evolving regulatory landscape, which can lead to better clinical outcomes and patient safety.

WHO:             Sam Osman, CEO of Cenduit

                      Rich Yang, vice president, Corporate Sales and Connected Solutions, Dexom

                      Dr. Paul Strumph, vice president, Clinical Development, Lexicon                                         Pharmaceuticals

                      Dr. Richard Bergenstal, executive director, International Diabetes Center                             (IDC), Par Nicollet

WHEN:            Tuesday, October 25, 2016 

                      2 p.m. EDT / 7 p.m. BST / 8 p.m. CEST

                      Duration: 1 hour

                      Click here to register for the free webinar.

DETAILS:       For media inquiries, please contact Ryan Boger at Largemouth Communications, (919) 459-6480, ryan@largemouthpr.com.

ABOUT:           Cenduit, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is the largest IRT specialist in the world with the expertise to empower sponsors for success by implementing a completely personalized system that puts them in control of their clinical trials. With the needs of investigator sites and patients top of mind, Cenduit offers clinical supply chain intelligence and clinical operations know-how through its IRT-driven services: patient randomization, patient reminders, drug supply management, and eClinical integration.  Cenduit has offices in the US, UK, Switzerland, India, and Japan, and global clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. For additional information, visit Cenduit online at www.cenduit.com; on Twitter @CenduitLLC or on LinkedIn at www.LinkedIn.com/Company/Cenduit.